Biliary Tract Cancer clinical trials

Explore recruiting biliary tract cancer clinical trials.

Recruiting biliary tract cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Biliary Tract Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer.

Czechia, Germany, Belgium, Italy, Spain, Poland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IMMUWHY - A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Germany, Poland, Italy, Belgium, France, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Biliary Tract Cancer trials by city

Biliary Tract Cancer in Toronto Biliary Tract Cancer in Vancouver Biliary Tract Cancer in Montreal Biliary Tract Cancer in Calgary Biliary Tract Cancer in Edmonton Biliary Tract Cancer in Ottawa Biliary Tract Cancer in Winnipeg Biliary Tract Cancer in Quebec City Biliary Tract Cancer in Hamilton Biliary Tract Cancer in Kitchener Biliary Tract Cancer in London Biliary Tract Cancer in Halifax Biliary Tract Cancer in New York Biliary Tract Cancer in Los Angeles Biliary Tract Cancer in Chicago Biliary Tract Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease